Fulltext

Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis

Sruamsiri R 1 , Wagner AK 2 , Ross-Degnan D 2 , Lu CY 2 , Dhippayom T 3 , Ngorsuraches S 4 Show all authors , Chaiyakunapruk N 5

Affiliations 

  • 1 Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Center of Pharmaceutical Outcomes Research, Naresuan University, Phitsanulok, Thailand Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA
  • 2 Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA
  • 3 Pharmaceutical Care Research Unit, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand
  • 4 College of Pharmacy, South Dakota State University, Brookings, South Dakota, USA
  • 5 Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Center of Pharmaceutical Outcomes Research, Naresuan University, Phitsanulok, Thailand School of Pharmacy, Monash University Malaysia, Selangor, Malaysia School of Population Health, University of Queensland, Brisbane, Australia School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA
BMJ Open, 2016;6(3):e008671.
PMID: 26988346 DOI: 10.1136/bmjopen-2015-008671

Abstract

In 2008, the Thai government introduced the 'high-cost medicines E2 access program' as a part of the National List of Essential Medicines to increase patient access to medicines, improve clinical outcomes and make medicines more affordable. Our objective was to examine whether the 'high-cost medicines E2 access program' achieved its goals.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications